International Journal of Endocrinology and Metabolism
Research Institute for Endocrine Sciences
140 Cases of Macroprolactinemia: Selected Clinical and Technical Laboratory Aspects
Authors
Abstract
Background: Macroprolactinemia can be an overlooked cause of hyperprolactinemia. To document the presence of macroprolactin in serum indirectly, an initial precipitation of the complexed prolactin (PRL) using polyethylene glycol (PEG) is followed by measurement of free and total prolactin by immunoassay.
Objectives: Adaptation of the PEG method to our PRL immunoassay to detect cases with predominant macroprolactinemia and to study the short- and long-term changes of the relationship between PRL forms.
Material and Methods: One hundred forty hyperprolactinemic patients (aged 17-72 years) in whom macroprolactin constituted ≥ 60% of the total PRL were included in our study. The predominance of macroprolactin was measured by adapted PEG procedure, followed by immunoradiometric and chemiluminescence methods.
Long-term observations with repeated serum PRL measurements were made in 20 cases. For another 20 of 41 patients with indications for metoclopramide (MCP) stimulation test, we analyzed short-term alterations in free and complexed PRL levels.
Results: Adjustment of the PEG method by testing samples in dilution minimized the interference of PEG in the immunoassays and let proper detection of predominant macroprolactinemia. During the long-term observations, the ratio of macroprolactin to total PRL remained relatively constant, independent of changes in total PRL levels. During the MCP test, in the majority of patients with macroprolactinemia (except those with associated PRL-secreting adenoma), an acute rise of PRL level followed by a rise in macroprolactin resulted in a short-term decrease in macroprolactin/total PRL ratio.
Conclusions: Confirmation of the predominance in serum of macroprolactin explains the discordance between the raised PRL level and scant of absent symptoms characteristic for hyperprolactinemia. Its proper detection can influence further management.
Please cite this paper as:
Jeske W, Glinicki P, Kapuscinska R, Zgliczynski W. 140 cases of Macroprolactinemia: Selected Clinical and Technical Laboratory Aspects,Poland. Int J Endocrinol Metabol. 2012;10(1) : 394-8. DOI: 10.5812/ijem.3600
Copyright © 2012 Kowsar M. P. Co. All rights reserved.
Highlights
Copyright
© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
Macroprolactinemia in Patients Presenting with Hyperandrogenic Symptoms and Hyperprolactinemia
Taghavi M, Sedigheh F. Macroprolactinemia in Patients Presenting with Hyperandrogenic Symptoms and Hyperprolactinemia. Int J Endocrinol Metab. 2008;6(3):. doi:
Is Morning Prolactin Level Sufficient for Diagnosis of Mild Hyperprolactinemia?
Ghasemi Basir HR, Razavi Z, Chehreghani M, Karami M, Dehghan A. Is Morning Prolactin Level Sufficient for Diagnosis of Mild Hyperprolactinemia?. J Kermanshah Univ Med Sci. 2019;23(1):e86003. doi: https://doi.org/10.5812/jkums.86003
Regulatory Effects of Dopamine, Oxytocin, and Thyrotropin- Releasing Hormone on the Release of Prolactin Variants From the Adenohypophysis of Lactating Rats
Navarro N, Castilla A, Mena F. Regulatory Effects of Dopamine, Oxytocin, and Thyrotropin- Releasing Hormone on the Release of Prolactin Variants From the Adenohypophysis of Lactating Rats. Int J Endocrinol Metab. 2011;9(3):. doi: https://doi.org/10.5812/Kowsar.1726913X.3179
Prolactin level in systemic lupus erythematosus patients
Zakeri Z, Narouie B, Shikhzadeh A, Nejati-afkham A, Ghasemi-rad M. Prolactin level in systemic lupus erythematosus patients. J Kermanshah Univ Med Sci. 2010;14(2):e79513. doi:
Evaluation of binding of FITC-prolactin conjugate to prolactin receptor
sirati Sabet M, Karami Tehrani F. Evaluation of binding of FITC-prolactin conjugate to prolactin receptor. J Inflamm Dis. 2024;10(4):e155258. doi:
- Scopus by DOI: 1
Last Update: 1 month ago
- Scopus by Title: 1
Last Update: 1 month ago
- Scopus by Title (Ref): 1
Last Update: 1 month ago
- CrossRef: 2
Last Update: 3 days ago